thalidomide has been researched along with Anemia, Sideroblastic in 5 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Anemia, Sideroblastic: Anemia characterized by the presence of erythroblasts containing excessive deposits of iron in the marrow.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Periodic fever was controlled in the first month after adalimumab therapy and IVIG replacement, but recurred in the second month." | 5.91 | Thalidomide as an Effective Treatment in Sideroblastic Anemia, Immunodeficiency, Periodic Fevers, and Developmental Delay (SIFD). ( Deng, M; Han, T; Li, Y; Mao, H; Mo, W, 2023) |
| "As lenalidomide has shown to be efficacious in both myelodysplastic syndromes and myeloproliferative neoplasms, we have treated 2 RARS-T patients, who were transfusion dependent, with lenalidomide." | 5.36 | Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis. ( de Wolf, JT; Huls, G; Mulder, AB; Rosati, S; van de Loosdrecht, AA; Vellenga, E, 2010) |
| "Anemia and iron overload are complications in both diseases and are managed similar to lower risk MDS." | 2.52 | Refractory anemia with ring sideroblasts and RARS with thrombocytosis. ( Patnaik, MM; Tefferi, A, 2015) |
| "Periodic fever was controlled in the first month after adalimumab therapy and IVIG replacement, but recurred in the second month." | 1.91 | Thalidomide as an Effective Treatment in Sideroblastic Anemia, Immunodeficiency, Periodic Fevers, and Developmental Delay (SIFD). ( Deng, M; Han, T; Li, Y; Mao, H; Mo, W, 2023) |
| "As lenalidomide has shown to be efficacious in both myelodysplastic syndromes and myeloproliferative neoplasms, we have treated 2 RARS-T patients, who were transfusion dependent, with lenalidomide." | 1.36 | Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis. ( de Wolf, JT; Huls, G; Mulder, AB; Rosati, S; van de Loosdrecht, AA; Vellenga, E, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Y | 1 |
| Deng, M | 1 |
| Han, T | 1 |
| Mo, W | 1 |
| Mao, H | 1 |
| Patnaik, MM | 1 |
| Tefferi, A | 2 |
| Huls, G | 1 |
| Mulder, AB | 1 |
| Rosati, S | 1 |
| van de Loosdrecht, AA | 1 |
| Vellenga, E | 1 |
| de Wolf, JT | 1 |
| Ziarkiewicz, M | 1 |
| Dwilewicz-Trojaczek, J | 1 |
| Pastwińska, A | 1 |
| Chmarzyńska, E | 1 |
| Paszkowska-Kowalewska, M | 1 |
| Koperski, Ł | 1 |
| Jędrzejczak, WW | 1 |
| Ziarkiewicz-Wróblewska, B | 1 |
| Steensma, DP | 1 |
2 reviews available for thalidomide and Anemia, Sideroblastic
| Article | Year |
|---|---|
Refractory anemia with ring sideroblasts and RARS with thrombocytosis.
Topics: Anemia, Refractory; Anemia, Sideroblastic; Angiogenesis Inhibitors; Aspirin; Female; Humans; Iron Ov | 2015 |
Risk-based management of myelodysplastic syndrome.
Topics: Anemia, Sideroblastic; Antilymphocyte Serum; Azacitidine; Benzoates; Decitabine; Deferasirox; DNA Mo | 2007 |
3 other studies available for thalidomide and Anemia, Sideroblastic
| Article | Year |
|---|---|
Thalidomide as an Effective Treatment in Sideroblastic Anemia, Immunodeficiency, Periodic Fevers, and Developmental Delay (SIFD).
Topics: Adalimumab; Anemia, Sideroblastic; Female; Fever; Humans; Immunoglobulins, Intravenous; Immunologic | 2023 |
Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis.
Topics: Aged, 80 and over; Anabolic Agents; Anemia, Refractory; Anemia, Sideroblastic; Antineoplastic Agents | 2010 |
Refractory anaemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T) with superimposed 5q-syndrome.
Topics: Aged; Anemia, Macrocytic; Anemia, Refractory; Anemia, Sideroblastic; Antineoplastic Agents; Bone Mar | 2010 |